Intelligencia offers an AI-driven platform and suite of decision-support solutions designed to minimize the risk of clinical development and accelerate scientific breakthroughs. Its tools help customers assess probability of success for pipeline drugs, identify optimal trial designs and additional indications, guide business-development decisions, and surface emerging technologies. The company works with top-10 and mid-size global biopharmaceutical companies, smaller biotechs, prominent research centers, and life-science investors. Intelligencia employs more than 40 people across its New York headquarters and an R&D center in Athens, Greece. Forbes included the company in its list of “America’s top 50 most promising AI companies.” The proceeds from the recent round will be used to expand the R&D team in Athens, grow sales and customer-success teams in the US and Europe, and integrate customers' proprietary data into its models to deepen product capabilities.

Total raised

$12M

Funding rounds

1

Latest round

Series A

Latest activity

Aug 2021